Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites

X Bai, B Zhang, P Wang, G Wang, J Li, D Wen… - Acta pharmacologica …, 2019 - nature.com
Myotoxicity is a significant factor contributing to the poor adherence and reduced
effectiveness in the treatment of statins. Genetic variations and high drug plasma exposure …
被引用次数：24 相关文章
[HTML] nih.gov

[HTML][HTML] Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites

X Bai, B Zhang, P Wang, G Wang, J Li… - Acta Pharmacologica …, 2019 - ncbi.nlm.nih.gov
Myotoxicity is a significant factor contributing to the poor adherence and reduced
effectiveness in the treatment of statins. Genetic variations and high drug plasma exposure …

Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites

X Bai, B Zhang, P Wang, GL Wang… - Acta …, 2019 - pubmed.ncbi.nlm.nih.gov
Myotoxicity is a significant factor contributing to the poor adherence and reduced
effectiveness in the treatment of statins. Genetic variations and high drug plasma exposure …

Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites.

X Bai, B Zhang, P Wang, GL Wang, JL Li… - Acta Pharmacologica …, 2018 - europepmc.org
Myotoxicity is a significant factor contributing to the poor adherence and reduced
effectiveness in the treatment of statins. Genetic variations and high drug plasma exposure …

Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites.

X Bai, B Zhang, P Wang, GL Wang, JL Li… - Acta Pharmacologica …, 2018 - europepmc.org
Myotoxicity is a significant factor contributing to the poor adherence and reduced
effectiveness in the treatment of statins. Genetic variations and high drug plasma exposure …